PL363245A1 - Compounds specific to adenosine a1 - Google Patents

Compounds specific to adenosine a1

Info

Publication number: PL363245A1
Authority: PL; Poland
Prior art keywords: adenosine; compounds specific; compounds; specific
Prior art date: 2000-12-01

Application number

PL01363245A

Other languages

Polish (pl)

Inventor

Arlindo L. Castelhano

Bryan Mckibben

David J. Witter

Original Assignee

Osi Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-01

Filing date

2001-11-30

Publication date

2004-11-15

2000-12-01 Priority claimed from US09/728,607 external-priority patent/US6664252B2/en

2000-12-01 Priority claimed from US09/728,316 external-priority patent/US6680322B2/en

2000-12-01 Priority claimed from US09/728,616 external-priority patent/US7160890B2/en

2001-11-30 Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.

2004-11-15 Publication of PL363245A1 publication Critical patent/PL363245A1/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL01363245A 2000-12-01 2001-11-30 Compounds specific to adenosine a1 PL363245A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US09/728,607 US6664252B2 (en)	1999-12-02	2000-12-01	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US09/728,316 US6680322B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A1 receptors and uses thereof
US09/728,616 US7160890B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A3 receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (1)

Publication Number	Publication Date
PL363245A1 true PL363245A1 (en)	2004-11-15

Family

ID=27419112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01363245A PL363245A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1

Country Status (20)

Country	Link
EP (1)	EP1347980A4 (en)
JP (1)	JP4579497B2 (en)
CN (1)	CN1263757C (en)
AP (1)	AP1893A (en)
AU (1)	AU2002248151B2 (en)
BR (1)	BR0115847A (en)
CA (1)	CA2430577A1 (en)
CZ (1)	CZ20031831A3 (en)
EA (1)	EA007254B1 (en)
HU (1)	HUP0400692A3 (en)
IL (1)	IL155962A0 (en)
ME (1)	MEP35308A (en)
MX (1)	MXPA03004717A (en)
NO (1)	NO327207B1 (en)
NZ (1)	NZ525885A (en)
OA (1)	OA13295A (en)
PL (1)	PL363245A1 (en)
WO (1)	WO2002057267A1 (en)
YU (1)	YU42703A (en)
ZA (1)	ZA200303729B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5090531A (en) *	1990-01-10	1992-02-25	Lord Corporation	Electrophoretic fluid differential
HUP0103836A3 (en)	1998-06-02	2003-05-28	Osi Pharmaceuticals Inc Uniond	Pyrrolo[2,3d]pyrimidine compositions and their use
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (en) *	2001-10-04	2003-04-10	Merck Patent Gmbh	New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
EP2050751A1 (en)	2001-11-30	2009-04-22	OSI Pharmaceuticals, Inc.	Compounds specific to adenosine A1 and A3 receptors and uses thereof
JP2005516005A (en) *	2001-12-07	2005-06-02	バーテクスファーマスーティカルズインコーポレイテッド	Pyrimidine-based compounds useful as GSK-3 inhibitors
DE60236458D1 (en)	2001-12-20	2010-07-01	Osi Pharm Inc	PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONISTIC COMPOUNDS, THEIR SYNTHESIS AND USE
EP1465631B1 (en)	2001-12-20	2010-02-24	OSI Pharmaceuticals, Inc.	Pyrimidine a2b selective antagonist compounds, their synthesis and use
US7199119B2 (en) *	2002-10-31	2007-04-03	Amgen Inc.	Antiinflammation agents
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (en)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
ES2878130T3 (en)	2006-04-25	2021-11-18	Astex Therapeutics Ltd	Derivatives of purine and deazapurine as pharmaceutical compounds
US20070260203A1 (en) *	2006-05-04	2007-11-08	Allergan, Inc.	Vasoactive agent intraocular implant
TW200808819A (en) *	2006-06-19	2008-02-16	Solvay Pharm Gmbh	Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
BRPI0818533B8 (en)	2007-10-11	2021-05-25	Astrazeneca Ab	compound, pharmaceutical composition, use of a compound, and, process for preparing a compound
US8349847B2 (en)	2008-01-11	2013-01-08	Durga Prasad Konakanchi	Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents
AR070127A1 (en)	2008-01-11	2010-03-17	Novartis Ag	PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
RS59568B1 (en)	2011-04-01	2019-12-31	Astrazeneca Ab	Therapeutic treatment
EP2785349B2 (en)	2011-11-30	2022-11-09	Astrazeneca AB	Combination treatment of cancer
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
MX2014014832A (en) *	2012-06-07	2015-02-12	Hoffmann La Roche	Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase.
BR112015031073B1 (en)	2013-06-21	2022-11-29	Zenith Epigenetics Ltd	BICYCLIC BROMODIMANIUM INHIBITORS AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS
CN105473581B (en) *	2013-06-21	2019-04-23	齐尼思表观遗传学有限公司	The dicyclic compound newly replaced as bromine structural domain inhibitor
WO2015015318A2 (en)	2013-07-31	2015-02-05	Zenith Epigenetics Corp.	Novel quinazolinones as bromodomain inhibitors
EP3227281A4 (en)	2014-12-01	2018-05-30	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
EP3230277B1 (en)	2014-12-11	2019-09-18	Zenith Epigenetics Ltd.	Substituted heterocycles as bromodomain inhibitors
WO2016097863A1 (en)	2014-12-17	2016-06-23	Zenith Epigenetics Corp.	Inhibitors of bromodomains
EA036122B1 (en) *	2015-01-20	2020-09-30	Уси Форчун Фармасьютикал Ко., Лтд	Jak inhibitor
PT3290418T (en)	2015-04-29	2019-07-16	Wuxi Fortune Pharmaceutical Co Ltd	Janus kinase (jak) inhibitors
EP3305788B1 (en)	2015-05-29	2020-08-05	Wuxi Fortune Pharmaceutical Co., Ltd	Janus kinase inhibitor
CN105771672B (en) *	2016-04-18	2018-03-02	天津工业大学	A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method
CN108570054B (en) *	2017-03-07	2021-07-16	广州再极医药科技有限公司	Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application
CN108017584B (en) *	2017-06-20	2021-03-23	南开大学	A3Small molecule antagonists of adenosine receptors
EP3802540A1 (en) *	2018-06-04	2021-04-14	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (en) *	2019-05-22	2021-08-31	北京大学深圳研究生院	Preparation method of 5-substituted beta-proline and derivatives thereof
CN110272373B (en) *	2019-07-02	2022-07-29	天津国际生物医药联合研究院	Selective adenosine A 1 Receptor antagonists and uses thereof
CN114085178A (en) *	2021-12-29	2022-02-25	苏州楚凯药业有限公司	Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ286892B6 (en) *	1992-12-17	2000-07-12	Pfizer	Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
US5780450A (en) *	1995-11-21	1998-07-14	Alcon Laboratories, Inc.	Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
HUP0103836A3 (en) *	1998-06-02	2003-05-28	Osi Pharmaceuticals Inc Uniond	Pyrrolo[2,3d]pyrimidine compositions and their use
ES2269217T3 (en) *	1999-12-02	2007-04-01	Osi Pharmaceuticals, Inc.	SPECIFIC COMPOUNDS FOR ADENOSINE A1, A2A AND A3 RECEPTORS AND THEIR USES.
EP2050751A1 (en) *	2001-11-30	2009-04-22	OSI Pharmaceuticals, Inc.	Compounds specific to adenosine A1 and A3 receptors and uses thereof

2001
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 IL IL15596201A patent/IL155962A0/en unknown
- 2001-11-30 YU YU42703A patent/YU42703A/en unknown
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/en unknown
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/en not_active Application Discontinuation
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/en unknown
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/en active IP Right Grant
- 2001-11-30 EA EA200300628A patent/EA007254B1/en not_active IP Right Cessation
- 2001-11-30 CN CNB018224601A patent/CN1263757C/en not_active Expired - Fee Related
- 2001-11-30 PL PL01363245A patent/PL363245A1/en not_active Application Discontinuation
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/en unknown
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/en not_active Expired - Fee Related
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU2002248151B2 (en)	2008-02-21
HUP0400692A2 (en)	2004-07-28
EA200300628A1 (en)	2003-12-25
EA007254B1 (en)	2006-08-25
EP1347980A4 (en)	2005-02-09
CN1263757C (en)	2006-07-12
AP2003002807A0 (en)	2003-06-30
CZ20031831A3 (en)	2004-05-12
IL155962A0 (en)	2003-12-23
MXPA03004717A (en)	2004-06-30
JP2004517896A (en)	2004-06-17
EP1347980A1 (en)	2003-10-01
NZ525885A (en)	2005-01-28
WO2002057267A1 (en)	2002-07-25
ZA200303729B (en)	2004-05-14
CN1489590A (en)	2004-04-14
MEP35308A (en)	2011-02-10
NO20032482L (en)	2003-07-28
AP1893A (en)	2008-09-23
HUP0400692A3 (en)	2007-09-28
CA2430577A1 (en)	2002-07-25
NO20032482D0 (en)	2003-06-02
YU42703A (en)	2006-03-03
NO327207B1 (en)	2009-05-11
OA13295A (en)	2007-04-13
BR0115847A (en)	2004-02-25
JP4579497B2 (en)	2010-11-10

Legal Events

Date	Code	Title	Description
2011-09-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL363245A1 (en)	2004-11-15	Compounds specific to adenosine a1
GB0022370D0 (en)	2000-10-25	Improvements to televisionn system
IL150934A0 (en)	2003-02-12	Pyrimidine compounds
GB0006513D0 (en)	2000-05-10	Improvements relating to converters
GB0021404D0 (en)	2000-10-18	Improvement in or to organic compounds
GB2360322B (en)	2003-08-06	Improvements relating to fasteners
GB2364338B (en)	2004-01-28	Improvements relating to construction
GB0028814D0 (en)	2001-01-10	Improvements relating to biosorbtion
GB9925417D0 (en)	1999-12-29	Improvements relating to screenboxes
GB2363331B (en)	2003-02-05	Supplement to enhance fertility
GB0121137D0 (en)	2001-10-24	Improvements to motorbility vehicles
GB2388346B (en)	2004-01-21	Improvements relating to vehicles
GB0013038D0 (en)	2000-07-19	Improvements relating to bicycles
GB2359528B (en)	2004-01-21	Improvements relating to vehicles
GB0029842D0 (en)	2001-01-24	Improvements relating to thermometers
GB0017107D0 (en)	2000-08-30	Improvements to velodromes
GB0025715D0 (en)	2000-12-06	Improvements relating to haribrushes
HRPK20000423B1 (en)	2002-06-30	Novel nucleosides
GB0022811D0 (en)	2000-11-01	Improvements relating to supports
GB2345464B (en)	2001-06-27	Improvements relating to forms
GB0007565D0 (en)	2000-05-17	Improvements relating to radiators
GB0029608D0 (en)	2001-01-17	Improvements relating to lamp-holder
GB0008226D0 (en)	2000-05-24	Improvements relating to spanners
GB9903159D0 (en)	1999-04-07	Improvements relating to window-walls
GB0026477D0 (en)	2000-12-13	Improvements relating to back supports